Patent details

301092 Product Name: fedratinib, of een farmaceutisch aanvaardbaar zout ervan

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301092
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP1278735
Status:
Expired Art. 14 (a) of the EC Regulations
Application number:
301092
Procedural language:
Dutch
First Applicant Residence Country:
Sweden (SE)

Marketing Authorization

Marketing Authorization Number:
EU/1/20/1514
Marketing Authorization Type:
EEA
Marketing Authorization Date:
09/02/2021
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
19/02/2021
First Marketing Authorization date:
09/02/2021
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
22/02/2021
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
26/02/2026
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
19/02/2021
 
 

 

Name:
AstraZeneca AB
Address:
-, 151 85 SÖDERTÄLJE, Sweden (SE)

Agent

1

Name:
dr. R.C. van Duijvenbode c.s.
From:
07/11/2025
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

2

Name:
ir. M.F.J.M. Ketelaars c.s.
From:
19/02/2021
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
07/11/2025

Publication

Bulletin

1

Bulletin Heading:
VRV
Journal edition number:
08/26
Publication date:
25/02/2026
Description:
Lapse or annulment

2

Bulletin Heading:
SPC
Journal edition number:
08/21
Publication date:
24/02/2021
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
20/09/2021 SPC Documents Annex SPC 1 PDF /9/9/8/2/5/0800652899/docs/301092_4_supplprotectioncertificate20210920115328904.pdf
20/09/2021 SPC Documents Annex SPC 2 PDF /9/9/8/2/5/0800652899/docs/301092_8_supplprotectioncertificate20210920115354229.pdf
20/09/2021 Incoming Correspondence Paper Accompanying letter incoming document 5 PDF /9/9/8/2/5/0800652899/docs/301092_9_incomingcorrespondencepaper20210920115707018.pdf
20/09/2021 SPC Documents Annex SPC 10 PDF /9/9/8/2/5/0800652899/docs/301092_12_supplprotectioncertificate20210920115259787.pdf
21/06/2021 Outgoing Correspondence Letter to applicant 1 PDF /9/9/8/2/5/0800652899/docs/301092_3_418298l173.pdf
18/06/2021 Incoming Correspondence Paper Accompanying letter incoming document 1 PDF /9/9/8/2/5/0800652899/docs/301092_0_incomingcorrespondencepaper20210618115331581.pdf
18/03/2021 Outgoing Correspondence Letter to applicant 6 PDF /9/9/8/2/5/0800652899/docs/301092_10_400007l173.pdf
22/02/2021 Outgoing Correspondence Confirmation receipt request 1 PDF /9/9/8/2/5/0800652899/docs/301092_1_395991l174.pdf
19/02/2021 SPC Documents Annex SPC 2 PDF /9/9/8/2/5/0800652899/docs/301092_2_supplprotectioncertificate20210222090058947.pdf
19/02/2021 SPC Documents Marketing Authorization SPC 4 PDF /9/9/8/2/5/0800652899/docs/301092_5_supplprotectioncertificate20210222085708161.pdf
19/02/2021 SPC Documents Annex SPC 13 PDF /9/9/8/2/5/0800652899/docs/301092_6_supplprotectioncertificate20210222090059020.pdf
19/02/2021 SPC Documents Summary of the characteristics of the product 19 PDF /9/9/8/2/5/0800652899/docs/301092_7_supplprotectioncertificate20210222090058862.pdf
19/02/2021 Application Form First filed application form 2 PDF /9/9/8/2/5/0800652899/docs/301092_11_applicationform20210222085436474.pdf